Last reviewed · How we verify
irradiated RBC
Irradiated red blood cells act as an immunogenic cellular vaccine to stimulate anti-tumor immune responses.
Irradiated red blood cells act as an immunogenic cellular vaccine to stimulate anti-tumor immune responses. Used for Pediatric hematologic malignancies (phase 3 development).
At a glance
| Generic name | irradiated RBC |
|---|---|
| Sponsor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
| Drug class | Cellular immunotherapy / Cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Irradiated autologous or allogeneic RBCs are treated with radiation to induce immunogenic cell death, which exposes damage-associated molecular patterns (DAMPs) and tumor-associated antigens. This triggers innate and adaptive immune responses, potentially enhancing anti-tumor immunity. The approach is designed to prime the immune system against malignant cells.
Approved indications
- Pediatric hematologic malignancies (phase 3 development)
Common side effects
- Infusion-related reactions
- Immune activation-related events
Key clinical trials
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion (PHASE1)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- A Multi-dimensional Evaluation of the Effects of Linear Accelerator X-ray Irradiation on Red Blood Cells
- RBC Irradiation, Anemia and Gut Injury
- Red Blood Cells From Umbilical Cord for Transfusion of Preterm Infants (NA)
- Prospective Validation of a Points Score System Predicting 30-day Survival
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: